SCHEDULE: Red Tree Venture Fund Trims Stake in Bicara Therapeutics

Red Tree Venture Fund and associated entities have reduced their ownership in Bicara Therapeutics to 4.8%, falling below the 5% reporting threshold.

Summary

• Red Tree Venture Fund, L.P., Red Tree GP, LLC, and Heath Lukatch, PhD, have filed an amended Schedule 13G indicating a reduction in their holdings.
• The reporting group now beneficially owns 3,170,509 shares of common stock.
• This ownership represents 4.8% of the company, based on 65,467,187 shares outstanding as of March 24, 2026.
• The filing confirms that the reporting persons now own 5% or less of the issuer's class of securities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as slightly negative to neutral; while it is a standard exit for a venture fund, the reduction below the 5% threshold removes a layer of transparency regarding their future selling activity.

Positives

• The reporting persons certify that the shares were not acquired to influence or change the control of the company.
• The group maintains a significant, albeit reduced, position of over 3.1 million shares.

Negatives

• A major institutional investor has reduced its stake to below the 5% threshold, which may indicate a cooling of conviction or a strategic exit.
• The reduction in ownership could lead to increased market supply of shares if the fund continues to sell its remaining 4.8% stake.

Risks

• Potential for further selling pressure if Red Tree Venture Fund continues to liquidate its position.
• Loss of a major 'anchor' institutional shareholder which can impact market sentiment and stock stability.

Future Outlook

The reporting persons have certified that their holding is passive and not intended to influence corporate control. Future filings will only be required if they cross back above the 5% threshold or if they are considered insiders under Section 16.

Management Comments

• The securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.

Industry Context

StockSavvy.ai notes that venture capital firms typically begin trimming positions in biotech companies 12 to 24 months post-IPO as they seek to distribute returns to their limited partners. This move by Red Tree is consistent with standard lifecycle management for venture-backed healthcare entities.

Comparison to Industry Standards

• A 4.8% stake is still a substantial holding but moves the investor out of the 'major shareholder' category (5%+) defined by the SEC.
• Similar stake reductions have been observed in peers like Acelyrin or RayzeBio following their initial public offerings as early-stage investors rebalance portfolios.

Stakeholder Impact

• Shareholders may experience downward pressure on the stock price if the fund continues to sell shares in the open market.
• The company loses the public designation of Red Tree as a 5% owner, which may affect institutional investor perception.

Next Steps

• Monitor for any further Form 4 filings if Heath Lukatch remains on the board of directors.
• Watch for potential price volatility as the market absorbs the news of a major holder trimming their position.

Key Dates

Recommendation

The reduction in stake by a key venture investor is a common occurrence in the biotech sector and does not necessarily reflect on the company's clinical prospects, but it does suggest that the stock may face technical headwinds from institutional selling in the near term.

Keywords

Bicara Therapeutics, Red Tree Venture Fund, Schedule 13G, Institutional Ownership, Biotechnology, Heath Lukatch, Equity Stake